🐋 BSX $1.6M LEAP Bet — Whale Positions for a Multi-Year Boston Scientific Recovery

📅 May 21, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just loaded up $1.6 MILLION into BSX January 2028 $70 calls — a 20-month LEAP bet that Boston Scientific can stage a major recovery from its current 52-week-low territory around $56. With BSX down roughly 47% over the past year after two consecutive guidance cuts, this isn't a short-term momentum play — it's a patient, high-conviction wager that the franchise stabilizes, the $14.5B Penumbra acquisition closes on schedule, and the stock reclaims ground it has lost. The premium paid is the max loss. Needs a big multi-quarter turnaround to pay off.

---

📊 Company Overview

Boston Scientific (BSX) is one of the world's largest medical device manufacturers, specializing in cardiovascular, electrophysiology, peripheral intervention, neuromodulation, and endoscopy products:

• Market Cap: ≈$84.2 billion (Public.com)
• Industry: Surgical & Medical Instruments & Apparatus
• Current Price: $56.71 (May 21, 2026) — near 52-week lows
• 52-Week Range: $52.52 – $109.50 (StockAnalysis)
• Primary Business: Farapulse pulsed-field ablation (PFA) catheters, Watchman left atrial appendage closure (LAAC) devices, SEISMIQ intravascular lithotripsy (IVL), neurovascular thrombectomy, spinal cord stimulation

BSX has been one of the worst-performing large-cap med-tech stocks over the past twelve months, falling ≈47% from highs above $109 after two guidance cuts rattled investor confidence in its flagship electrophysiology and Watchman franchises. It is, however, still a growing business — Q1 2026 net sales came in at $5.2 billion, up +11.6% reported. The stock is a fallen-growth-story-at-a-price-reset, not a company in crisis.

---

💰 The Option Flow Breakdown

The Tape (May 21, 2026 @ 13:37:40):

OCC Symbol: BSX20280121C70

🤓 What This Actually Means

This is a fresh long-dated LEAP position — a Buy to Open (BTO) bet that BSX recovers significantly over the next 20 months. Here's what the numbers tell us:

• 💸 Premium paid: $1.6M ($8.95 per contract × 1,800 contracts × 100 shares)
• 🎯 Strike distance: $70 strike is ≈23% above the current spot price of $56.71 — meaning BSX needs to rally ≈23% just to reach breakeven at expiration (excluding the $8.95 premium paid)
• 📊 True breakeven: $70 + $8.95 = $78.95 — BSX needs to trade above $78.95 at January 2028 expiration for this position to profit
• ⏰ Time horizon: 20 months to expiration (January 21, 2028) — this is not a trade for the next earnings report; it's a bet on a multi-quarter franchise recovery
• 🔥 Clearly fresh open: Vol/OI ratio of ≈12 (1,800 volume vs 151 prior open interest) confirms this is a brand-new position, not someone closing an existing bet
• 📅 Symbolic timing: January 21, 2028 expiration falls almost exactly two years after BSX announced the $14.5B Penumbra acquisition on January 15, 2026 — whether intentional or coincidental, the LEAP essentially runs through the full post-acquisition integration window

What's really happening here:

Real talk: this trader is betting on a fallen-knife recovery in a medical-device giant that has taken two gut punches in six months. BSX went from ≈$110 to ≈$56 on back-to-back guidance cuts in February and April 2026. This LEAP buyer is saying "the damage is done, the stock has reset, and the next 20 months are a catalyst-rich window." They are willing to pay $1.6M for the right to profit if BSX can climb back toward its previous trading range.

The max loss is 100% of the $1.6M premium — no more, no less. This is defined risk, but the full amount is at stake if BSX stays below $70 through January 2028.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

BSX is one of the worst large-cap performers in the medical device space year-to-date. The stock peaked above $109 in late 2025, then collapsed in two sharp legs — the first on February 4, 2026 (a 17.6% single-day drop after Q4 2025 results) and the second on April 22, 2026 (Q1 2026 guidance cut). The stock briefly bounced toward $65 in late April before sliding back into the mid-$50s. As of May 21, 2026 it trades at $56.71 — roughly 5% above its 52-week low of $52.52.

Key observations from the chart:

• 📉 Massive drawdown: ≈47% from 52-week high — the stock is in deep value-recovery territory
• 🛡️ Attempting to base: The bounce from early-May lows shows some buying interest; the stock is ≈5% off the 52-week floor
• 📊 Fallen growth stock: Two guidance cuts compressed the multiple dramatically; the stock now prices in a much more modest growth outlook
• ⚠️ Still in downtrend: No clear technical reversal yet — the LEAP buyer is getting in ahead of confirmation, not after it

Gamma-Based Support & Resistance Analysis

Current Price: $56.71 | GEX reference price: $57.05

The gamma exposure map for BSX shows a relatively clean picture with two dominant levels that will anchor near-term price action:

🔵 Support Levels (Put Gamma Below Price):

• $55 — Strong support with 6.74B total gamma; put gamma (4.99B) significantly outweighs call gamma (1.75B), meaning market makers have heavy hedging commitments to buy the stock on dips toward this level. This is the near-term floor the whale is relying on to hold while the recovery thesis plays out.
• $50 — Deeper structural floor with 3.38B total gamma; mostly put-heavy, so a meaningful cushion if $55 breaks

🟠 Resistance Levels (Call Gamma Above Price):

• $60 — Very Strong resistance at 10.44B total gamma; this is the single largest gamma concentration in the entire BSX chain. Market makers will systematically sell into rallies as BSX approaches $60, creating a natural ceiling. Breaking through $60 is the first real test for a recovery move.
• $70 — Second major resistance wall at 7.89B total gamma; almost entirely call gamma (7.49B), which is precisely where this LEAP is struck. The fact that $70 is a dominant gamma wall confirms this as a recognized institutional strike — there's significant existing open interest and dealer positioning at exactly this level.
• $65 — Notable gamma at 4.61B; call-heavy (3.48B), another checkpoint on the way from $60 to $70

What this means for traders:

BSX is currently sandwiched between $55 support and the heavy $60 resistance. The $60 level is the immediate gating hurdle — if BSX cannot recover above $60 convincingly, the path to $70 (where this LEAP becomes at-the-money) is structurally blocked. The good news: the LEAP buyer has 20 months, and these gamma walls will roll as old expiries close out and new hedging is set up at different strikes.

Net GEX Bias: The dominant call gamma at $60 and $70 suggests market makers are net short calls at higher strikes — which can work as a magnet pulling the stock upward as those strikes become relevant. For a recovery thesis, that dynamic is a mild tailwind.

Implied Move Analysis

Options market pricing for upcoming expirations:

• 📅 Weekly (May 22, 2026 — 1 day away): ±$1.15 (±2.01%) → Range: $55.91 – $58.21

The market is pricing only a ±2% move for BSX over the next single trading day — which makes sense with no immediate catalyst on the calendar. The weekly range of $55.91 to $58.21 reinforces the gamma-defined support at $55 and resistance at $60.

Translation for regular folks:

Short-term, BSX is in a holding pattern. The options market expects the stock to stay roughly between $56 and $58 through tomorrow's weekly expiry. For the LEAP buyer, this near-term range is noise — what matters is where BSX trades in January 2028. The current low IV environment on short-dated contracts means the LEAP premium of $8.95 is essentially a 20-month "time value plus recovery optionality" payment. There are no major implied-move events priced for next week, but the Q2 2026 earnings on July 29, 2026 will be a significant volatility event as the market reassesses the recovery narrative.

---

🎪 Catalysts

🔥 Recent Events (Already Happened)

Q1 2026 Earnings — Reported April 22, 2026 (Second Guidance Cut) 📊

BSX delivered $5.203 billion in Q1 net sales (+11.6% reported / +9.4% organic) and beat adjusted EPS consensus ($0.80 vs $0.79 expected, per MassDevice). Electrophysiology hit $905 million (+22%) — strong in absolute terms, but flagged as decelerating. The problem: full-year 2026 organic growth guidance was cut to 6.5%–8.0% from prior 10.0%–11.0%, and full-year adjusted EPS guidance was cut to $3.34–$3.41. CEO Mike Mahoney cited "unanticipated headwinds" across electrophysiology, Watchman, and Urology. This second consecutive cut — after the initial February 4, 2026 shock — is the central overhang on the stock and the reason BSX trades near 52-week lows.

February 4, 2026 — 17.6% Crash (First Guidance Cut) 📉

BSX fell $16.12 in a single session after Q4 2025 results showed slower-than-modeled U.S. EP sales and a 2026 organic guide that came in far below analyst assumptions of ≈25% EP growth. A federal securities fraud class action was subsequently filed alleging management hid weakening U.S. EP trends — a litigation overhang that remains open.

AVANT GUARD PFA Trial — April 23–26, 2026 (NEJM Publication) 🩺

Major clinical win: the AVANT GUARD trial demonstrated Farapulse PFA as statistically superior to anti-arrhythmic drugs as first-line therapy in persistent atrial fibrillation, cutting relative risk of treatment failure by 54% (hazard ratio 0.46) over one year in 310 randomized patients. Published simultaneously in the New England Journal of Medicine. This is a structural positive for the long-term PFA market — but the stock barely responded because sentiment around the EP franchise is already damaged.

FARAPOINT PFA Catheter — FDA Approval (2026) ✅

BSX received FDA approval for the FARAPOINT PFA catheter for linear and focal lesions in a single catheter, paired with the Faraview software module. Expands the procedural versatility of the Farapulse PFA platform.

Penumbra Shareholders Approve Merger — May 6, 2026 🤝

Penumbra shareholders voted to approve the $14.5B merger with BSX at the May 6 special meeting. The deal — structured at $374/share (≈73% cash) — adds Penumbra's ≈$1.4 billion of mechanical thrombectomy and neurovascular revenue (stroke, pulmonary embolism, acute limb ischemia). Regulatory clearance (HSR) is the remaining gating item for the expected H2 2026 close.

SEISMIQ 4CE Coronary IVL FRACTURE Trial — May 19, 2026 💊

The 420-patient FRACTURE IDE pivotal trial met its primary safety endpoint: 93.3% freedom from MACE at 30 days (vs 86.2% performance goal), presented at EuroPCR 2026. BSX plans to use the data to support an FDA regulatory filing for its coronary IVL catheter — a potential entry into the multi-billion-dollar calcified-coronary-artery market currently led by Shockwave (now J&J).

$2 Billion Accelerated Share Repurchase — May 2026 💵

BSX entered a $2 billion accelerated share repurchase agreement — a notable capital-return signal at depressed prices that reduces share count and signals management confidence.

---

🚀 Upcoming Catalysts (Next 6 Months)

Bernstein 42nd Annual Strategic Decisions Conference — May 27, 2026 🎤

CEO Mike Mahoney and Interventional Cardiology CMO Janar Sathananthan will participate in a 50-minute Q&A at the Bernstein conference — just 6 days away. This is an important near-term setup: any tone change on EP stabilization, Watchman trendlines, or Penumbra regulatory timing could move the stock. Watch for management language around whether the Q1 headwinds are stabilizing.

Q2 2026 Earnings — July 29, 2026, 8:00 a.m. ET 📊

The next hard catalyst is the Q2 2026 earnings report on July 29. Company guidance for Q2 calls for organic growth of 5%–7%, adjusted EPS of $0.82–$0.84. Street consensus: EPS ≈$0.83, revenue ≈$5.40B. This is the first real test of whether Q1's "unanticipated headwinds" were a one-time reset or the beginning of a prolonged deceleration. Key metrics to watch: U.S. EP sequential trend, Watchman growth rate (company guided mid-teens), Urology, and any update on Penumbra regulatory timing.

Penumbra Deal Close — Expected H2 2026 🏥

With shareholder approval already secured, the remaining gating item is HSR/antitrust clearance. A successful close is the single largest structural catalyst for the LEAP buyer's thesis — it adds ≈$1.4B of fast-growing thrombectomy revenue and establishes BSX as a leader in neurovascular intervention.

Nalu Medical Close — Expected H1 2026 (Imminent) 🧠

The $533M Nalu Medical acquisition (chronic-pain micro-IPG neuromodulation) is expected to close in first-half 2026, meaning it could close within weeks. Adds a fast-growing neuromodulation asset.

SEISMIQ 4CE Coronary IVL — FDA Filing (Timeline TBD) 📋

Positive FRACTURE pivotal data from May 2026 positions BSX for an FDA regulatory filing for the coronary IVL catheter, opening a potential path into the coronary lithotripsy market currently led by Shockwave/J&J. No FDA approval is expected within the LEAP window, but the filing and any priority-review signal would be a positive catalyst.

Farapulse Persistent-AF Label Expansion 🩺

The AVANT GUARD NEJM superiority data sets up BSX for potential label expansion of Farapulse into first-line persistent AF — a much larger patient population than the current approved indication. Commercial uptake commentary at Q2 and Q3 calls will be the key read-through.

Q3 2026 Earnings — Late October 2026 📊

The second major earnings checkpoint inside the 20-month LEAP window. By Q3, Penumbra should be closed and initial integration commentary should be available — critical for the bull case.

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, catalyst timeline, and analyst consensus as the framework:

📈 Bull Case (25% probability)

Target: $75–$90 by January 2028 | LEAP pays off

How we get there:

• 💪 Q2 and Q3 2026 earnings show EP share loss has stabilized — management regains credibility and the multiple begins to re-rate
• 🏥 Penumbra deal closes on schedule in H2 2026 with no major antitrust complications; the ≈$1.4B of fast-growing thrombectomy revenue starts being valued by the market
• 🩺 Farapulse AVANT GUARD data drives meaningful persistent-AF label expansion commercially; EP growth re-accelerates from a lower base
• 💊 SEISMIQ 4CE FDA filing submitted and well-received, creating a new multi-billion-dollar coronary IVL growth story heading into 2027
• 💵 The $2B share buyback at depressed prices reduces float and provides mechanical support
• 📊 Analyst average price target of ≈$91.67 gets partly realized as the overhang from guidance cuts clears; even a modest re-rating toward $80 puts the $78.95 breakeven in play

LEAP P&L in this case:

• BSX at $85 on January 21, 2028: Call worth ≈$15.00 → profit of ≈$6.05/share × 1,800 contracts × 100 = ≈$1.09M gain (≈68% ROI on the $1.6M outlay)
• BSX at $90: Call worth ≈$20.00 → profit of ≈$11.05/share → ≈$1.99M gain (≈124% ROI)

🎯 Base Case (45% probability)

Target: $58–$72 by January 2028 | Partial recovery, mixed outcome

Most likely scenario:

• ✅ BSX stabilizes in the $58–$68 range through 2026 as EP headwinds moderate but do not fully reverse
• 📊 Penumbra closes but Year-1 EPS dilution ($0.06–$0.08) and integration complexity weigh on near-term estimates
• 🔄 Stock gradually grinds higher as credibility recovers but never breaks decisively above the $70 gamma wall before January 2028
• ⚖️ The LEAP expires partially in-the-money (if BSX is $71–$78) or slightly out-of-the-money (if BSX is $65–$70), resulting in a partial loss or close to breakeven

Key inflection point: If BSX cannot clear the heavy $60 gamma resistance within the next 2–3 quarters, the path to $70 by January 2028 becomes increasingly narrow.

📉 Bear Case (30% probability)

Target: $45–$58 by January 2028 | LEAP expires worthless

What could go wrong:

• 😰 EP/Farapulse share loss accelerates further at Q2 — Medtronic, J&J, Abbott, and Kardium all gain incremental PFA share and BSX cannot find the bottom of the deceleration
• 🚨 Penumbra deal faces a DOJ/FTC second request, delaying the H2 2026 close into 2027 and adding execution/integration risk
• ⚖️ Securities class-action litigation creates ongoing headline risk and potential settlement costs; management credibility stays impaired
• 📉 Watchman and Urology — the other two named drivers of the guidance cut — do not recover, pressuring total company organic growth below even the reduced 6.5%–8.0% full-year target
• 💀 BSX stays range-bound in the $50s–$60s for 20 months, the LEAP expires worthless, and the whale loses all $1.6M

LEAP P&L in this case:

• BSX at $65 on January 21, 2028: Call worth $0 (out-of-the-money) → loss of full $8.95/share × 1,800 × 100 = −$1.61M (100% loss)
• BSX at $55: Call worth $0 → full loss of −$1.61M

---

💡 Trading Ideas

🛡️ Conservative: Watch and Wait for Q2 Earnings Confirmation

Play: Hold off on entering any new BSX position until after the July 29, 2026 Q2 earnings report — the first real test of whether the guidance reset is a one-time event or a prolonged decline.

Why this works:

• ⏰ The LEAP buyer has 20 months — retail traders don't need to chase the same trade today
• 📊 Q2 earnings will either confirm EP stabilization (buy signal) or reveal additional deterioration (stay away)
• 💸 Entering after earnings confirmation trades some upside for a dramatically higher probability of success
• 🎯 A post-earnings entry in the $55–$60 range, assuming results are stabilizing, could find BSX stock itself offering strong risk/reward without the option premium cost
• 📈 If BSX breaks above the $60 gamma wall on strong Q2 results, that technical confirmation alone improves the recovery thesis substantially

Action plan: Watch the May 27 Bernstein conference for tone change. Then mark July 29 on your calendar. Look for sequential EP stability, Watchman growth at or above mid-teens guide, and any Penumbra regulatory update. If Q2 delivers a clean beat with stable guidance — that's the signal to act.

Risk level: Minimal (no position) | Skill level: Beginner-friendly

---

⚖️ Balanced: Shorter-Dated Call Spread Targeting the $60 Gamma Wall

Play: Buy a call spread targeting the $60 resistance level in the October 2026 timeframe — capturing the Q2 earnings catalyst and the Penumbra closing milestone in a defined-risk structure.

Why this works:

• 🎯 The $60 gamma wall (10.44B total gamma — the strongest level in the BSX chain) is the natural near-term bull-case target; a spread maximizes the probability of capturing a move from $57 to $60 without paying for the longer-dated $70 recovery thesis
• 💰 Defined risk: pay the net debit, max loss is capped at that debit
• ⏰ October 2026 expiration captures Q2 earnings (July 29), Penumbra closing news, and the early Farapulse persistent-AF commercialization update
• 📊 Much lower capital requirement than the whale's LEAP, with a more achievable near-term target ($60 vs $78.95 breakeven on the LEAP)

Structure: Buy October 2026 $57.50 calls, sell October 2026 $62.50 calls — roughly a $5-wide spread

Estimated P&L (ballpark, verify with current quotes):

• 💰 Net debit: ≈$1.50–$2.00 per spread ($150–$200 per 1-lot)
• 📈 Max profit: $3.00–$3.50 per spread if BSX above $62.50 at October expiry (≈150–200% ROI)
• 📉 Max loss: full debit paid (defined, no surprises)
• 🎯 Breakeven: ≈$59.00–$59.50

Position sizing: Risk only 2%–3% of portfolio per position on a defined-risk recovery play.

Risk level: Moderate (defined risk, directional bullish) | Skill level: Intermediate

---

🚀 Aggressive: Mirror the Whale (Scaled Down LEAP)

Play: Buy 1–5 contracts of the BSX January 2028 $70 calls (BSX20280121C70) alongside the institutional order at the current ≈$8.95 price.

Why this could work:

• 🐋 The whale paid $1.6M at ≈$8.95 — retail traders with 1–5 contracts pay $895–$4,475 total, with identical risk/reward dynamics
• ⏰ The 20-month window is genuinely long enough for multiple catalysts to materialize: 3 earnings reports, Penumbra close, Nalu close, coronary IVL filing, AVANT GUARD label expansion
• 📊 The analyst consensus target of ≈$91.67 (per Public.com) implies 60%+ upside if any fraction of that Street view is realized — the $70 strike would be well in the money
• 💰 Maximum loss is limited to the premium paid — no margin requirement, no assignment risk

Why this is aggressive:

• ❗ BSX needs to rally ≈39% from current levels just to break even on the LEAP at $78.95
• ❗ The stock is in a confirmed downtrend after two guidance cuts — buying OTM calls on a falling knife requires high conviction
• ❗ The full premium ($895 per contract at $8.95) goes to zero if BSX stays below $70 through January 2028 — a 30% probability scenario per our bear case

CRITICAL: Only buy a position size you are fully prepared to lose 100% of. This is a lottery-ticket structure on a recovery thesis, not a low-risk trade.

Risk level: EXTREME (100% of premium at risk) | Skill level: Advanced / High-conviction only

---

⚠️ Risk Factors

Don't get caught by these potential landmines:

• 📉 Two guidance cuts, damaged credibility: February 4 and April 22, 2026 guidance reductions — back-to-back — damaged management's track record significantly. When the same team says "we didn't see this coming" twice in six months, the market demands proof of stabilization before granting a re-rating. The LEAP breakeven at $78.95 requires BSX to recover to levels it held after the first guidance cut. That's asking a lot from a management team currently under a cloud.

• ⚖️ Securities fraud class action: A federal lawsuit covers the July 23, 2025 – February 3, 2026 class period, alleging management misrepresented U.S. EP market conditions. A settlement or unfavorable ruling is an incremental headline risk over the 20-month LEAP window.

• 🏥 Penumbra deal risk: The $14.5B acquisition is $0.06–$0.08 dilutive to adjusted EPS in Year 1. Any DOJ/FTC second request extending the review beyond H2 2026 would delay accretion, frustrate investors, and potentially reignite concerns about BSX's capital allocation and leverage. The deal is a long-term positive but a near-term EPS headwind.

• 🔥 EP share loss could accelerate: Medtronic, J&J MedTech, Abbott, and Kardium are all actively taking PFA share from Farapulse. The EP segment still grew +22% to $905M in Q1 — but the growth rate is decelerating from a very high prior base. If competition intensifies and BSX loses further incremental share, a third guidance cut becomes a real risk and the stock could revisit or break the $52.52 52-week low.

• 😰 Watchman and Urology still soft: Both were named explicitly in the April guidance cut — Watchman missing its own internal targets at +19.2% (guided to mid-teens going forward) and Urology softening. Three simultaneous franchise headwinds make a quick recovery harder to execute.

• 💸 Deep OTM + 20 months = time decay pressure: The $70 strike is 23% above current spot. Even if BSX stabilizes and begins to recover, the call's theta (time decay) works against the buyer every day. The stock needs to move meaningfully higher, not just stabilize, for the premium to hold its value. A flat-to-modestly-higher BSX scenario through 2027 is a losing trade for the LEAP buyer.

• 💰 Falling-knife environment: Near 52-week lows is an emotionally compelling entry point — but technical trends are still down. There is no confirmed reversal yet. The LEAP bet is a faith-based recovery call being made before the market shows evidence of the turn.

---

🎯 The Bottom Line

Here's the deal: A whale just bet $1.6 million that Boston Scientific — a medical device giant now trading near 52-week lows — can stage a meaningful multi-year recovery by January 2028. This is not a flip trade. It's a patient, high-conviction LEAP bet on a franchise that has been punished hard but still generates over $20 billion in annual revenue run-rate with a deep pipeline of catalysts converging over the next 20 months.

What this trade tells us:

• 🐋 This is someone with conviction in the recovery thesis — the Vol/OI ratio of ≈12 confirms a fresh open, not a hedge on an existing position
• 🎯 The $70 strike is ≈23% OTM; the $78.95 breakeven is ≈39% above spot — this LEAP only pays off if the Farapulse + Penumbra + IVL narrative actually plays out over multiple quarters
• 💰 Max loss is exactly $1.6M — no surprises, no margin calls. It's a defined-risk bet on a big recovery
• 📊 The January 2028 expiration gives three full earnings cycles (Q2 July 29, Q3 October, Q4 early 2027) plus the full Penumbra integration window to be proven right

If you're following the recovery thesis:

• ✅ Wait for the May 27 Bernstein conference for the first management tone check since Q1 earnings
• 📅 Mark July 29, 2026 as the pivotal moment — Q2 earnings will either confirm the floor or reveal a third leg down
• 🎯 A break above the $60 gamma wall on strong Q2 results would be the first technical signal that the recovery is real
• 🛡️ If you want exposure to this thesis, consider the call spread structure described above rather than naked LEAP — lower capital requirement, more achievable near-term target

If you're skeptical:

• ⚠️ Two guidance cuts from the same management team is a serious credibility problem — be patient and demand proof before committing
• 📉 BSX at $52.52 (52-week low) is only ≈8% below current price — the downside floor is not far away and a third guidance cut or Penumbra delay could test it
• ❌ Never size up on a falling-knife recovery bet — if you participate at all, keep it to money you're comfortable losing 100% of

Mark your calendar — Key dates:

• 📅 May 27, 2026 — Bernstein Strategic Decisions Conference, CEO tone check on EP stabilization and Penumbra
• 📅 H1 2026 (imminent) — Nalu Medical acquisition close expected
• 📅 July 29, 2026, 8:00 a.m. ET — Q2 2026 Earnings — THE pivotal test for this LEAP thesis
• 📅 H2 2026 — Penumbra deal expected to close — the biggest structural catalyst
• 📅 Late October 2026 — Q3 2026 Earnings — first post-Penumbra close results
• 📅 January 21, 2028 — LEAP expiration; BSX needs to be above $78.95 for the trade to profit

Final verdict: The BSX recovery thesis is real — the pipeline is genuinely deep (AVANT GUARD, Penumbra, SEISMIQ 4CE, $2B buyback), and the stock at $56 against an analyst average target of ≈$91.67 implies significant upside if franchises stabilize. But the two-cut credibility hit is also real, and this LEAP requires ≈39% upside just to break even. This is a high-risk, high-reward bet for patient traders who believe in a multi-year med-tech recovery story — not a near-term trade. The whale has 20 months and $1.6M to prove the thesis. Respect the position size, respect the risk, and don't overcommit.

Be patient. Wait for Q2 confirmation. The Penumbra story will take time to play out. 💪

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Past performance does not guarantee future results. The BSX January 2028 $70 calls are deep out-of-the-money with a breakeven of $78.95 — there is a meaningful probability (estimated 30% in our bear case) that this position expires completely worthless. Never invest more than you can afford to lose 100% of in speculative options positions. Always conduct your own research and consider consulting a licensed financial advisor before trading. This trade involves a 20-month time horizon; short-term price movements should not be used to gauge the health of this position.

---

About Boston Scientific: Boston Scientific is a global medical device leader with a market cap of ≈$84.2 billion, operating across cardiovascular, electrophysiology, peripheral intervention, neuromodulation, and endoscopy. Its flagship products include the Farapulse pulsed-field ablation system, Watchman left atrial appendage closure device, and the SEISMIQ intravascular lithotripsy platform.